Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Modelling geographic variation in the cost-effectiveness of control policies for infectious vector diseases: the example of Chagas disease.

Castillo-Riquelme M, Chalabi Z, Lord J, Guhl F, Campbell-Lendrum D, Davies C, Fox-Rushby J.

J Health Econ. 2008 Mar;27(2):405-26. doi: 10.1016/j.jhealeco.2007.04.005. Epub 2007 Dec 5.

PMID:
18222556
[PubMed - indexed for MEDLINE]
2.

Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.

Shepherd J, Jones J, Frampton GK, Tanajewski L, Turner D, Price A.

Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. Review.

PMID:
18547499
[PubMed - indexed for MEDLINE]
Free Article
3.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

PMID:
18513468
[PubMed - indexed for MEDLINE]
Free Article
4.

Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.

Rojnik K, Naversnik K, Mateović-Rojnik T, Primiczakelj M.

Value Health. 2008 Mar-Apr;11(2):139-48. doi: 10.1111/j.1524-4733.2007.00223.x.

PMID:
18380626
[PubMed - indexed for MEDLINE]
5.

Resource allocation for control of infectious diseases in multiple independent populations: beyond cost-effectiveness analysis.

Brandeau ML, Zaric GS, Richter A.

J Health Econ. 2003 Jul;22(4):575-98.

PMID:
12842316
[PubMed - indexed for MEDLINE]
6.

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.

Kim SY, Goldie SJ.

Pharmacoeconomics. 2008;26(3):191-215. Review.

PMID:
18282015
[PubMed - indexed for MEDLINE]
7.

A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.

Tumeh JW, Shenoy PJ, Moore SG, Kauh J, Flowers C.

Am J Clin Oncol. 2009 Feb;32(1):49-55. doi: 10.1097/COC.0b013e31817c6a4d.

PMID:
19194125
[PubMed - indexed for MEDLINE]
8.

Estimating 'costs' for cost-effectiveness analysis.

Miners A.

Pharmacoeconomics. 2008;26(9):745-51.

PMID:
18767895
[PubMed - indexed for MEDLINE]
9.

Cost effectiveness of drug-eluting stents in Belgian practice: healthcare payer perspective.

Neyt M, De Laet C, De Ridder A, Van Brabandt H.

Pharmacoeconomics. 2009;27(4):313-27. doi: 10.2165/00019053-200927040-00004.

PMID:
19485427
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of group psychotherapy for depression in Uganda.

Siskind D, Baingana F, Kim J.

J Ment Health Policy Econ. 2008 Sep;11(3):127-33.

PMID:
18806302
[PubMed - indexed for MEDLINE]
11.

The value of health.

Groot W, van den Brink HM.

BMC Health Serv Res. 2008 Jun 25;8:136. doi: 10.1186/1472-6963-8-136.

PMID:
18578854
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Cost-effectiveness analysis: from science to application.

Berger ML, Teutsch S.

Med Care. 2005 Jul;43(7 Suppl):49-53.

PMID:
16056009
[PubMed - indexed for MEDLINE]
13.

Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.

Arnold E, Yuan Y, Iloeje U, Cook G.

Appl Health Econ Health Policy. 2008;6(4):231-46. doi: 10.2165/00148365-200806040-00005.

PMID:
19382822
[PubMed - indexed for MEDLINE]
14.

Using costs in cost-effectiveness models for chronic diseases: lessons from diabetes.

Hoerger TJ.

Med Care. 2009 Jul;47(7 Suppl 1):S21-7. doi: 10.1097/MLR.0b013e3181a2bf32.

PMID:
19536014
[PubMed - indexed for MEDLINE]
15.

Cost-effectiveness analysis and health policy.

Torgerson DJ.

Nestle Nutr Workshop Ser Clin Perform Programme. 2009;12:95-104. doi: 10.1159/000235671. Epub 2009 Aug 20.

PMID:
19858689
[PubMed - indexed for MEDLINE]
16.

Cost-effectiveness of Chagas disease interventions in latin america and the Caribbean: Markov models.

Wilson LS, Strosberg AM, Barrio K.

Am J Trop Med Hyg. 2005 Nov;73(5):901-10.

PMID:
16282301
[PubMed - indexed for MEDLINE]
Free Article
17.

Cost-effectiveness of escitalopram for generalized anxiety disorder in Canada.

Iskedjian M, Walker JH, Bereza BG, Le Melledo JM, Einarson TR.

Curr Med Res Opin. 2008 May;24(5):1539-48. doi: 10.1185/030079908X297277 . Epub 2008 Apr 15.

PMID:
18416886
[PubMed - indexed for MEDLINE]
18.

An innovative enterostomal therapy nurse model of community wound care delivery: a retrospective cost-effectiveness analysis.

Harris C, Shannon R.

J Wound Ostomy Continence Nurs. 2008 Mar-Apr;35(2):169-83; discussion 184-5. doi: 10.1097/01.WON.0000313639.37247.c0.

PMID:
18344791
[PubMed - indexed for MEDLINE]
19.

[Combating infectious disease using mathematical modelling].

Kretzschmar M, Wallinga J, Coutinho RA.

Ned Tijdschr Geneeskd. 2006 Sep 9;150(36):1965-70. Review. Dutch.

PMID:
17002184
[PubMed - indexed for MEDLINE]
20.

A systematic review of the clinical effectiveness and cost-effectiveness and economic modelling of minimal incision total hip replacement approaches in the management of arthritic disease of the hip.

de Verteuil R, Imamura M, Zhu S, Glazener C, Fraser C, Munro N, Hutchison J, Grant A, Coyle D, Coyle K, Vale L.

Health Technol Assess. 2008 Jun;12(26):iii-iv, ix-223. Review.

PMID:
18513467
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk